Acer Therapeutics (ACER) Stock Price, News & Analysis

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACER, but not buy additional shares or sell existing shares.
View ACER analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year price targets for Acer Therapeutics' stock. Their ACER share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 127.2% from the stock's current price.
View analysts price targets for ACER or view top-rated stocks among Wall Street analysts.

Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings data on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05.

64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).